Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. The company is headquartered in San Diego, California and currently employs 44 full-time employees. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. The company is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.
Follow-Up Questions
Ainos Inc의 CEO는 누구입니까?
Mr. Chun-Hsien Tsai은 2021부터 회사에 합류한 Ainos Inc의 Chairman of the Board입니다.
AIMD 주식의 가격 성능은 어떻습니까?
AIMD의 현재 가격은 $3.51이며, 전 거래일에 decreased 0% 하였습니다.
Ainos Inc의 주요 사업 주제나 업종은 무엇입니까?
Ainos Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
